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without VSD). We speculated that the de-
creasing incidence of postoperative seizures
compared with previous reports, particularly
among children undergoing biventricular
repair, was due to improved (intraoperative
and perioperative) management strategies.
It is likely that specific anatomic subgroups
previously considered to be at high risk for
postoperative seizure activity are no longer
at increased risk. As Hashmi, Hanif, and
O’Reilly note, we did not report duration of
seizure activity. However, we did evaluate
the number of seizures in the monitoring
period as a risk factor for worse neurodevel-
opmental outcome. The number of seizures
was not predictive of scores on either the
Mental Developmental Index (MDI) or the
Psychomotor Developmental Index (PDI) of
the Bayley Scales of Infant Development-.
Hashmi, Hanif, and O’Reilly also ask
whether the EEG examiners were blinded
to the fact that the child had a seizure in the
postoperative period. As the recent study
evaluated neurodevelopmental outcomes,
we assume that they do not mean the EEG
examiners, but rather the psychologists
performing the 1-year neurodevelopmental
evaluation, who were blinded to the child’s
seizure status.
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Internal thoracic artery grafts to
right coronary system
To the Editor:
We read with interest the article by Sabik
and coworkers,1 “Influence of Patient
Characteristics and Arterial Grafts on Free-
dom From Coronary Reoperation.” We
congratulate the team of surgeons from The
Cleveland Clinic for coming up with an-
other landmark article that will be of im-
mense benefit to both surgeons and patients
around the world.
We agree with Sabik and coworkers1
that aggressive risk factor modifications
and more extensive use of arterial grafts are
necessary for reduction of reoperations.
They identified a reduced early hazard
phase when there was incomplete right cor-
onary artery (RCA) revascularization. Dur-
ing their discussion, they presented no
valid reason for this apparently anomalous
finding and remarked “It is hard to under-
stand how incomplete revascularization to
the RCA and elevated triglyceride level
both lowered the early risk of reopera-
tions.”1
We have had similar experience with
patients with a diffusely diseased RCA ei-
ther bifurcating or trifurcating into small-
caliber vessels, with none suitable for
grafting. In this situation, not grafting the
RCA would not disturb the native collater-
als and would probably result in better im-
mediate postoperative results, as demon-
strated by Sabik and coworkers.1
Endarterectomy in this situation would still
result in incomplete revascularization, be-
cause the plaque cannot be removed com-
pletely from the small distal vessels, con-
sistent with the poor early results seen with
RCA revascularization.
In the later part of the study, internal
thoracic artery grafting to RCA did reduce
reoperation rates. Sabik and coworkers
should specify what proportion of these
patients in the early and later portions of
the study had the posterior descending ar-
tery grafted, in contrast to distal RCA
grafts. Posterior descending artery grafts
show significantly better patency rates and
are associated with lower postoperative
morbidity.2 We have observed fewer post-
operative coronary events when the poste-
rior descending artery is grafted instead of
the distal RCA. We believe that the benefit
observed in the later part of the study may
have been due to a trend toward posterior
descending artery grafting.
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Monobloc or separate aortic and
mitral homografts?
To the Editor:
Recently, Obadia and associates1 reported
their experience with monobloc aorto-mitral
homograft for extensive endocarditis. Since
1994, we have performed combined aortic
and mitral valve replacement with homo-
grafts in 6 patients (mean age: 31 7 years).
However, two separated valves were used
for the reasons explained below. The etiol-
ogy of the valve disease was rheumatic
(n  3), congenital (n  1), or bacterial
endocarditis with abscess of the aorto-
mitral junction (n  2). One patient was
undergoing a third reoperation for pros-
thetic valve dehiscence. As in Obadia’s
technique,1 the first step of the operation
was fixation of the papillary muscles,
whose exposure can be very difficult. It was
anticipated that a bulky aorto-mitral mono-
bloc, once lowered into position, would
somewhat obstruct the access to the papil-
lary muscles. In addition, the use of an
aorto-mitral monobloc would necessarily
have restricted the panel of available sizes,
increasing the risk of mismatch, which has
been shown as a factor of mitral homograft
dysfunction.2 Thus, it was decided to im-
plant two separate homografts. The aortic
and the mitral valve were approached sep-
arately through the standard incisions. Part
of the papillary muscle sutures were in-
serted through the aortic orifice. The mitral
valve homograft was inserted according to
a previously described technique, which in-
variably included ring annuloplasty.2 This
latter technical detail is probably relevant
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since the use of a prosthetic ring seems to
greatly enhance the durability of the mitral
homograft.2 Using the wall of the aortic
homograft and a low insertion of the valve
so as to exclude the aorto-mitral abscess
when present made unnecessary any recon-
struction of the left atrial roof. The mean
bypass time was 192  11 minutes, which
is comparable with the monobloc aorto-
mitral technique according to Obadia and
suggests that the preservation of an intact
aorto-mitral continuity did not spare any
significant ischemic time. Among our 6 pa-
tients, there was no in-hospital death. One
patient died at 47 months of cerebral hem-
orrhage, and there was one reoperation for
recurrence of endocarditis at 69 months. Af-
ter a mean follow-up of 59 6 months, the
remaining 4 patients were asymptomatic
and 1 patient had had from a normal preg-
nancy. In conclusion, although technically
challenging, a combined aortic and mitral
valve replacement with two separate ho-
mografts can also be a valid option in
highly selected cases.
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Reply to the Editor:
The comment by Christophe Acar discusses
the alternative between monobloc aorto-
mitral homograft, as my colleagues and I
have proposed, or separate aortic homograft
plus mitral homograft, which he appears to
prefer. In our opinion, the indications are
not strictly the same.1 The patients reported
in Acar’s series were very different from
ours. Our patients had much more severe
disease and always had a history of multi-
ple reoperations with at least one if not two
prostheses in place. The justification for a
monobloc procedure is related to the pres-
ence of a large abscess in the aorto-mitral
curtain, and the main value of monobloc
reconstruction is to allow complete resec-
tion of the aorto-mitral curtain and there-
fore all of the infected tissues. This is im-
possible with a separate aortic replacement
plus mitral replacement, which obviously
leaves all or part of the subaortic curtain in
place.
In contrast with Acar’s claim, the tech-
nique that we propose is not necessarily
more difficult to perform. Access to the
papillary muscle is largely facilitated by a
very large aorto-mitral orifice obtained af-
ter resection of all of the subaortic curtain,
providing excellent exposure of the papil-
lary muscles, which facilitates suture of the
mitral homograft.
Christophe Acar has an extensive experi-
ence with mitral homografts, and his studies
inspired us to systematically insert a mitral
ring onto the mitral homograft to limit, as
rightly suggested by Acar, the risks of mis-
match, which are effectively a risk factor for
secondary homograft dysfunction.
In conclusion, as suggested by Christo-
phe Acar, separate homografts could be
reserved for patients with distinct aortic
and mitral lesions. In contrast, we think it is
logical to maintain the principle of a mono-
bloc procedure, which is the only technique
allowing resection of aorto-mitral abscesses.
I believe that the most important point is
the quality of the resection phase. Ho-
mograft reconstruction has not been dem-
onstrated to be superior to monobloc me-
chanical prosthesis, which can therefore be
preferred in the absence of an available
monobloc homograft in the tissue bank.
Jean-François Obadia, MD, PhD
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What patients want: A new
biological era in valvular prostheses
To the Editor:
We read with great interest the article by
Smedira and associates.1 It deals with the
important issue of valvular disease and
gives further data to help surgeons to
choose the right prosthesis.
One of the points that attracted our at-
tention was the aim of the study. As the
authors clearly expressed, the renewed in-
terest in biologic prostheses reflects in-
creased attention given by patients to the
biologic valve.
We are experiencing a similar trend. An
increasing number of patients are well in-
formed about the benefits and risks of all
types of prostheses when they are admitted
to the hospital for valve replacement. Con-
trary to guidelines, a growing number of
patients prefer to choose a biologic pros-
thesis, even if they are young and will
require a prosthesis replacement. The rea-
sons for this trend vary. First, a patient who
must undergo valve replacement is inter-
ested not only in life expectancy but also in
quality of life. Anticoagulant therapy is
considered a major limitation to quality of
life, especially in those young patients who
have an active lifestyle and do not want to
change their habits. Moreover, they are
more concerned by the risk of thromboem-
bolism linked to mechanical prostheses and
to anticoagulation than by reoperation. Pa-
tients actually know that mortality and
morbidity risks after reoperation are de-
creasing.
Another important topic that is leading
more patients to choose a biologic prosthe-
sis is the strong belief in technology and
technologic advances. Starting with the
consideration that the mean life expect-
ancy of biologic prostheses is calculated
on valves implanted 15 to 20 years ago,
newer prostheses probably will last longer
because they are constructed with new
techniques and treated with new anticalci-
fication treatments. Moreover, those pa-
tients strongly believe that future replace-
ment prostheses probably will have an even
longer life expectancy.
The surgeon must take note of this new
trend. In our institute we are implanting an
increased number of biologic prostheses
even in younger patients. Even the number
of Bentall operations performed with bio-
logic valves is increasing, as is the number
of valve repairs. Moreover, we have started
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